Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alpen pharma d.o.o. - vodenoetanolni ekstrakt zlatice toranj, toranj gusije travi sam toranj rastavića - oralna tečnost - 7.9 ml/10 ml+ 7.9 ml/10 ml+ 7.9 ml/10 ml - 100 ml oralne tečnosti sadrži: 79 ml etanolnog ekstrakta (1:1,5 2,1) herbe zlatice, herbe gusije trave i herbe rastavića (4,2:1,4:1)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alpen pharma d.o.o. - vodenoetanolni ekstrakt zlatice toranj, toranj gusije travi sam toranj rastavića - oralna tečnost - 7.9 ml/10 ml+ 7.9 ml/10 ml+ 7.9 ml/10 ml - 100 ml oralne tečnosti sadrži: 79 ml etanolnog ekstrakta (1:1,5 2,1) herbe zlatice, herbe gusije trave i herbe rastavića (4,2:1,4:1)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alpen pharma gmbh, steinenfeld 3, zell am harmersbach, njemačka - tekući ekstrakt (1:1,5 &ndash 2,1) iz mješavine zlatničine zeleni, zeleni guščarskog petoprsta i zeleni poljske preslice (4,2:1,4 : 1), ekstrakcijsko otapalo: etanol 50% (v/v) - oralne kapi, otopina - urbroj: 10 ml (= 9,5 g) phytocyst oralnih kapi, otopine sadrži: 7,9 ml tekućeg ekstrakta (1 : 1,5 – 2,1) iz mješavine solidago gigantea ait. i/ili solidago canadensis l., herba (zlatničina zelen), potentilla anserina l., herba (zelen guščarskog petoprsta) i equisetum arvense l., herba (zelen poljske preslice) (4,2 : 1,4 : 1). ekstrakcijsko otapalo: etanol 50 % v/v 30 kapi jednako je 1,3 ml otopine

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi b.v. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation; lymphoma - Иммуностимуляторы, - mozobil je indiciran u kombinaciji sa stimulacije granulocitnih kolonija stimulirajući faktor za poboljšanje mobilizacije krvotvornih matičnih stanica periferne krvi za prikupljanje i naknadne autologne transplantacije u bolesnika s mijelomom čije stanice mobilizirati slabo.

Europska Unija - hrvatski - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastična sredstva - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Europska Unija - hrvatski - EMA (European Medicines Agency)

neovii biotech gmbh - catumaxomab - ascites; cancer - drugi antineoplastični agensi - removab je indiciran za intraperitonealno liječenje malignih ascitesa u bolesnika s epcam-pozitivnim karcinomima gdje standardna terapija nije dostupna ili više nije izvediva.

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastična sredstva - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zentiva pharma d.o.o. - lenalidomid - kapsula, tvrda - 2,5 mg/1 kapsula - jedna kapsula, tvrda sadrži: 2,5 mg lenalidomida